FAQ

Is the ReWalk™ suitable for me?

In its current configuration and functionality, the ReWalk™ is suitable for lower-limb mobility impaired adults who have functioning hands, arms and shoulders, as well as the ability to stand (healthy skeleton and cardio-vascular system). An approval from a physician is required.

When will the ReWalk™ be released for the market?

The ReWalk™ will be ready for world-wide commercial deployment by 2010.

What will be the price of the ReWalk™?

The price hasn’t been established yet. However, we’re targeting for an annual consumer (end-user) price comparable with typical average annual expenses of people confined to wheelchairs.

Will the ReWalk™ be reimbursable by health-insurance?

Based on our surveys and on precedents, we strongly believe that the ReWalk™ will be partially or fully reimbursable, depending on the region (country).

Is Argo interested in strategic partnerships?

Argo is seeking strategic partners who will be able to effectively provide marketing / sales, training, technical support and any other customer support function. Companies which manufacture and market / sale orthotic equipment (e.g. prosthetics) or mobility equipment (e.g. wheelchairs) or organizations which operate orthopedic and / or neurologic rehabilitation centers or workshops are our prime targets for strategic partnerships. Companies / organizations which have at least nationwide (countrywide) presence in sales and / or service will be preferential candidates.

Can I become a ReWalk™ distributor?

Argo welcomes contacts with companies who are well established in the rehabilitation sector in their respective countries. Currently, it is too early to initiate marketing efforts and to establish commercial relations with distributors, worldwide. All information received will be kept and Argo will approach prospective distributors in due course.

Can I invest in Argo?

Argo is currently in the midst of a capital investment recruitment round and we will gladly consider private or institutional investments of a minimum of $500,000 in return for equity.

Please contact us if you have an interest in receiving additional information on an investment opportunity.

Can I participate in the ReWalk™ clinical trials?

The ReWalk™ is currently being tested in Israel. Further clinical trials are planned within the next year in several rehabilitation centers in Europe and in the USA.

Persons who show interest in participating in the clinical trials should periodically check on our website for specific Information regarding participation possibilities and application procedures. Please do not initiate unauthorized contacts with anyone at any of the rehabilitation centers.

Do I have an advantage in signing-up early on for possible purchase of the ReWalk™?

Argo does not manage a "waiting list" for the ReWalk™. However, we welcome contact details of prospective end-users of the ReWalk™ in order to update them on relevant events and dates, such as expected commercial availability dates and details of the points of sale in different global regions.

How do I contact Argo?

The best way to reach us is by Emails addressed to info@argomedtec.com.

We will do our best to respond to all inquiries promptly. However, due to the current intense media exposure of the ReWalk™, Argo is “flooded” with inquiries which might cause some delays in our response, for which we apologize in advance.